We summarize the cardiac safety profile of bleximenib for acute leukemias, with findings from the cAMeLot-1 and ALE1002 trials, which were presented at #EHA2026. Explore the full visual abstract here: bit.ly/4gJD2uO #AMLsm #leusm #MedEd

New publication 📝 Results from a retrospective study, published in @BMTjournal, show that in adults with AML undergoing allo-HSCT with PTCy-based GvHD prophylaxis, requiring two induction courses significantly increased relapse incidence vs one course (27% vs 19.3%; p = 0.003), but did not impact OS. Learn more about AML: bit.ly/4keAq8j #AMLsm #leusm #MedNews #MedEd

New publication 📝 Results from the final analysis of the phase III LACEWING study, published in @haematologica, show gilteritinib + azacitidine vs azacitidine monotherapy did not improve median OS in patients with ND FLT3m AML (9.82 months vs 9.23 months; p = 0.182). Learn more about FLT3m AML: bit.ly/4b4vpuG #AMLsm #leusm #MedNews #MedEd

New publication 📝  Results from a retrospective real-world study published in @BrJHaem show gilteritinib followed by allo-HSCT and subsequent gilteritinib maintenance achieved 92% 1-year OS vs 34% with gilteritinib monotherapy in R/R FLT3m AML. Learn more about FLT3m AML: bit.ly/4b4vpuG #AMLsm #leusm #MedNews #MedEd

Recent congresses highlighted the expanding role of menin inhibitors in AML, including in combination strategies and investigation in ND AML. Read our article summarizing the latest updates from #ASH25, #ASCO26 and #EHA2026 here: bit.ly/4AlCZgv #AMLsm #leusm #MedEd

New publication 📝 Results from a retrospective, real-world analysis, published in @haematologica, show that venetoclax + high-dose cytarabine + mitoxantrone achieved a CR/CRi rate of 69% in patients with R/R AML, with a 1-year OS rate of 58%. Learn more about R/R AML: bit.ly/4cEaOym #AMLsm #leusm #MedNews #MedEd

We summarize key efficacy and safety updates for menin inhibitors in AML reported at #ASH25, #ASCO26 and #EHA2026. Read our article here: bit.ly/4AlCZgv #AMLsm #leusm #MedEd

🚨 News 🚨 @US_FDA clears the IND application for TBS-2025, a VISTA-inhibiting antibody, allowing a phase Ib study evaluating its safety and efficacy in patients with R/R NPM1-mutated #AML following menin inhibitor therapy. Read more: prn.to/4yD1dks #AMLsm #leusm #MedNews

Cardiac safety data from the cAMeLot-1 and ALE1002 trials demonstrate that bleximenib, as monotherapy or in combination with AML-directed therapies, does not prolong QTc in patients with acute leukemias. We summarize these data in our latest visual abstract: bit.ly/4gJD2uO #AMLsm #leusm #MedEd

New publication 📝 Results from a retrospective analysis, published in @BloodPortfolio, estimate 25.8 million cumulative life-years saved across major blood cancer types in the US since 1964. Learn more about AML: bit.ly/4keAq8j #AMLsm #ALL #leusm #lymsm #MedNews #MedEd

September is #BloodCancerAwarenessMonth! This month, we're shining a light on leukemia — one of the three primary forms of blood cancer. Visit bit.ly/4keAq8j, where we offer reliable, comprehensive, and current medical education on #AcuteMyeloidLeukemia, designed for healthcare professionals around the globe. #amlsm #leusm

New publication 📝 Results from a post hoc analysis, published in the European Journal of Haematology, show that 13% of patients with R/R IDH1m AML receiving olutasidenib ± azacitidine proceeded to allo-HSCT, of whom 73% achieved CR/CRh prior to transplant. Learn more about IDH1m AML: bit.ly/47zhuMi #AMLsm #leusm #MedNews #MedEd

New publication 📝 Results from a retrospective study, published in @JournalCancer, show older age (p = 0.029), FLT3-ITD co-mutation (p = 0.004), extramedullary disease (p < 0.001), and performance status >2 (p < 0.001) are predictors of worse OS in patients with ND NPM1m AML treated with high-intensity chemotherapy. Learn more about NPM1m AML: bit.ly/3OtuEUk #AMLsm #leusm #MedNews #MedEd

New publication 📝 Results from the phase II OPTI-AML trial, published in @BloodPortfolio, show Aza + 14-day Ven did not demonstrate non-inferiority for CR vs Aza + 28-day Ven in older/unfit adults with ND AML. Learn more about ND AML: bit.ly/3NSE3Vk #AMLsm #leusm #MedNews #MedEd

New publication 📝 Results from a PETHEMA registry study, published in @Haematologica, show SRSF2 (p = 0.006), ETV6 (p = 0.015), and FLT3-ITD (p = 0.020) co-mutations confer poorer OS in patients with NPM1m AML. Learn more about NPM1m AML: bit.ly/3OtuEUk #AMLsm #leusm #MedNews #MedEd

🚨NEWS🚨 @FDA grants orphan drug designation to BAL0891, a small-molecule dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1), for the treatment of AML. Read more: bit.ly/3UgBHTu #AMLsm #leusm #MedEd #MedNews

New publication 📝 A modified Delphi consensus study, published in @e_JHaem, provided recommendations supporting earlier allo-HSCT referral, standardized MDT protocols, and clear communication to improve transplant access for patients with AML in the UK. Learn more about allo-HSCT: bit.ly/4tj1Wp3 #AMLsm #leusm #MedNews #MedEd

New publication 📝 Results from the long-term follow-up of a phase II study, published in @haematologica, show oral decitabine/cedazuridine + venetoclax achieved an ORR of 75% in older/unfit patients with ND de novo AML vs 58% in those with ND secondary AML. Learn more about ND AML: bit.ly/3NSE3Vk #AMLsm #leusm #MedNews #MedEd

New publication 📝 Subgroup analysis results from the UK NCRI AML18 trial, published in @BloodPortfolio, show treatment with vs without quizartinib significantly improved OS in older patients with FLT3-mutated AML (5-year OS, 47% vs 25%; p = 0.024). Learn more about FLT3 inhibitors in AML: bit.ly/3TWw10D #AMLsm #leusm #MedNews #MedEd

New publication 📝 Results from the phase I/II ASCERTAIN-V trial, published in @NEJM, show all-oral decitabine/cedazuridine + venetoclax had no drug–drug interactions, and achieved a CR in 47% of patients with ND AML ineligible for intensive chemotherapy in phase IIb. Learn more about ND AML: bit.ly/3NSE3Vk #AMLsm #leusm #MedNews #MedEd